Pancreatic Cancer Research

ResearcherWenzhou Medical UniversityActive in the last 2 years

Keqing Shi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-5070-3834; OpenAlex author ID A5079375772. Sources: OpenAlex.

Their work

Papers
12 (first author 5, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
26
Papers, trials and grants by year

2017: 1 paper · 2018: 2 papers · 2019: 2 papers · 2020: 5 papers · 2021: 1 paper · 2022: none · 2023: none · 2024: 1 paper

Papers 12

  1. Pancreatic cancer pathology image segmentation with channel and spatial long-range dependencies. Last author DOI 10.1016/j.compbiomed.2023.107844↗
  2. Development and validation of the trans-omics model for pancreatic adenocarcinoma. Last author DOI 10.2217/epi-2020-0184↗
  3. Pseudostellaria heterophylla Extract Polysaccharide H-1-2 Suppresses Pancreatic Cancer by Inhibiting Hypoxia-Induced AG2. First author DOI 10.1016/j.omto.2020.03.007↗
  4. Identification of a competing endogenous RNA network associated with prognosis of pancreatic adenocarcinoma. Co-author DOI 10.1186/s12935-020-01243-6↗
  5. Correction to: Identification of a competing endogenous RNA network associated with prognosis of pancreatic adenocarcinoma. Co-author DOI 10.1186/s12935-020-01381-x↗
  6. Corrigendum: Natural Killer Cell-Derived Exosomal miR-3607-3p Inhibits Pancreatic Cancer Progression by Targeting IL-26. First author DOI 10.3389/fimmu.2020.00277↗
  7. STRAP as a New Therapeutic Target for Poor Prognosis of Pancreatic Ductal Adenocarcinoma Patients Mainly Caused by TP53 Mutation. Co-author DOI 10.3389/fonc.2020.594224↗
  8. The DNA methylation profile of non-coding RNAs improves prognosis prediction for pancreatic adenocarcinoma. First author DOI 10.1186/s12935-019-0828-8↗
  9. Natural Killer Cell-Derived Exosomal miR-3607-3p Inhibits Pancreatic Cancer Progression by Targeting IL-26. First author DOI 10.3389/fimmu.2019.02819↗
  10. Brusatol Enhances the Chemotherapy Efficacy of Gemcitabine in Pancreatic Cancer via the Nrf2 Signalling Pathway. Co-author DOI 10.1155/2018/2360427↗
  11. Mechanism Comparison of Gemcitabine and Dasatinib-Resistant Pancreatic Cancer by Integrating mRNA and miRNA Expression Profiles. Co-author DOI 10.7754/clin.lab.2018.171124↗
  12. A nomogram based on preoperative inflammatory markers predicting the overall survival of pancreatic ductal adenocarcinoma. First author DOI 10.1111/jgh.13676↗

Closest collaborators

The 25 strongest of 26 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Wanqing Weng · 4 shared papers, 2019–2021 · strength 0.46
  2. Weiguo Huang · 4 shared papers, 2019–2021 · strength 0.46
  3. Mengtao Zhou · 4 shared papers, 2018–2020 · strength 0.39
  4. Zhuo Lin · 3 shared papers, 2020–2021 · strength 0.38
  5. Zhaomin Chen · 1 shared paper, 2024 · strength 0.23
  6. Yunfeng Shan · 2 shared papers, 2020 · strength 0.23
  7. Hongwei Sun · 2 shared papers, 2019–2020 · strength 0.23
  8. Bicheng Chen · 2 shared papers, 2018–2019 · strength 0.21
  9. Shengjie Dai · 2 shared papers, 2019–2020 · strength 0.20
  10. Mengtao Zhou · 2 shared papers, 2017–2020 · strength 0.19
  11. Bicheng Chen · 2 shared papers, 2018–2020 · strength 0.18
  12. Yukai Xiang · 2 shared papers, 2018–2019 · strength 0.16
  13. Zongjing Chen · 1 shared paper, 2018 · strength 0.12
  14. Hongwei Sun · 1 shared paper, 2020 · strength 0.11
  15. Wenqian Huang · 1 shared paper, 2020 · strength 0.11
  16. Chenlei Zheng · 1 shared paper, 2020 · strength 0.11
  17. Hongbao Yang · 1 shared paper, 2020 · strength 0.11
  18. Percy David Papa Akuetteh · 1 shared paper, 2020 · strength 0.11
  19. Shanshan Hu · 1 shared paper, 2020 · strength 0.11
  20. Qiyu Zhang · 1 shared paper, 2020 · strength 0.11
  21. Jie Zhang · 1 shared paper, 2019 · strength 0.09
  22. Yangyang Guo · 1 shared paper, 2019 · strength 0.09
  23. Jie Xu · 1 shared paper, 2017 · strength 0.08
  24. Jie Zhang · 1 shared paper, 2018 · strength 0.07
  25. Dinglai Yu · 1 shared paper, 2018 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.